We analyzed outcomes for 668 patients who had systemic treatment for chronic graft-versushost disease (GVHD) to assess the utility of early treatment change for exacerbation of chronic GVHD as a surrogate for survival endpoints in clinical trials. Fifty-six percent of patients had treatment change within 2 years after diagnosis of chronic GVHD. The median onset of treatment change was 4.4 months (range, 0.3 -50 months). The cumulative incidence of nonrelapse mortality (NRM) at 2 years was 16%, and overall survival at 2 years was 74%. In timedependent Cox models, treatment change was associated with an increase in risk of NRM (hazard ratio, 2.53; 95% CI, 1.7-3.7; p < .0001). The hazard ratio was attenuated by 6% per month of delay in treatment change. Our results confirm that exacerbation of chronic GVHD is associated with an increased risk of NRM and with decreased survival, but the strength of this association is not large enough to allow the use of early exacerbation as a surrogate for survival endpoints in clinical trials. Other measures of clinical benefit, such as response, will need to be developed as endpoints in phase II trials for patients with chronic GVHD.
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Introduction
Chronic graft-versus-host disease (GVHD) is the major determinant of late non-relapse morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). [1] [2] [3] In addition to increased risk of nonrelapse mortality, patients with chronic GVHD have decreased performance, impaired quality of life and delayed immune reconstitution. [4] [5] [6] In most cases, resolution of chronic GVHD requires prolonged systemic immunosuppressive treatment. 7 Clinical trials of treatment for chronic GVHD have been hampered by the lack of easily documented early indicators of clinical benefit. Demonstration of prolonged survival or a shorter time to resolution of chronic GVHD may be feasible for pivotal phase III studies, but ascertainment of these endpoints occurs too late to be useful for phase II studies. 8, 9 An NIH consensus development project recommended an approach that could be used to measure response in clinical trials for treatment of chronic GVHD, but these recommendations have not yet been validated. 10 Implementation of these recommendations has been difficult, because they require a much larger burden of documentation than would ordinarily be required for clinical practice. In addition, certain features of chronic GVHD have important qualitative characteristics such as sclerosis and intensity of erythema that are not readily amenable to quantitative measurement.
Identification of more accessible validated endpoints indicating clinical benefit could facilitate the conduct of clinical trials in chronic GVHD. Kim et al. 11 recently proposed that an early flare or exacerbation of chronic GVHD could be used as an endpoint in clinical trials.
Early flare was strongly associated with decreased GVHD-specific survival, i.e., increased nonrelapse mortality. GVHD-specific survival at 2 years was 96% among 27 patients who had no flare, 65% among 34 patients with a first flare more than 78 days after diagnosis of chronic GVHD, and 33% among 35 patients who had a first flare within 78 days after diagnosis.
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Prompted by this report, we reviewed outcomes among patients with chronic GVHD at our 4 center in an effort to validate these results and to assess the utility of early flare as a surrogate for survival in clinical trials.
Patient and methods
We reviewed data collected in real time for 668 consecutive patients who were given initial systemic treatment for chronic GVHD diagnosed after May 1, 2001 following a first allogeneic HCT after myeloablative or non-myeloablative conditioning regimens. Patients who had recurrent malignancy before the diagnosis of chronic GVHD were excluded. NIH criteria were used for the diagnosis of classic chronic GVHD, except that an ocular clinical score of 2 or 3 without Schirmer's test was accepted as sufficient to define ocular involvement. 12 The cohort did not include patients with persistent, recurrent or delayed-onset acute GVHD. 12 We used the first treatment change as a surrogate for exacerbation of chronic GVHD, and we evaluated the association of treatment change with non-relapse mortality and overall survival.
Change of treatment
Dates and the reasons for change of treatment after the initial systemic treatment for chronic GVHD have been prospectively recorded at our center since May, 2001. Change of treatment was defined as 1) addition of a new systemic medication to control chronic GVHD, 2)
increase in the dose of prednisone to at least 1 mg/kg every other day for control of chronic GVHD, or 3) addition of a topical treatment for chronic GVHD involving a previously unaffected site. Change of treatment because of toxicity alone was not included, since the focus of the study was to use change of treatment as a surrogate for "flare" or inadequate control of chronic GVHD.
Statistical methods
Results were analyzed according to information available as of May 2008. Cox proportional hazards regression was used to identify risk factors for treatment change, and time-dependent Cox proportional hazards regression was used to evaluate the association of treatment change with mortality. Cumulative incidence estimates and confidence intervals (CIs) were evaluated as previously described 13 . Factors evaluated for association with treatment change included age of the patient at time of transplant, recipient HLA-mismatching (i.e., any graft-versus-host mismatching at HLA A, B, C, DRB1 or DQB1), donor type (i.e., unrelated and related), recipient and donor gender, type of graft (i.e., marrow or mobilized blood), type of preparative regimen (i.e., nonmyelobative, myeloablative with and without total body irradiation), onset of chronic GVHD during systemic glucocorticoid treatment, type of onset of chronic GVHD (i.e., progressive, de novo, quiescent), platelet count less than 100,000/μL at onset of chronic GVHD, and sites involved at the onset of chronic GVHD.
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Results
The median patient age at transplant of the cohort was 46.7 years (range, 0.5 -73 years). Four hundred and forty-six patients (67%) received a myeloablative conditioning regimen pretransplant. Other demographic and graft characteristics for the 668 patients are summarized in Table 1 and Figure 1 . Chronic GVHD was diagnosed during steroid treatment in 37% of the patients, and 30% had a platelet count <100,000/μL at the onset of chronic GVHD. Overall, 49% of patients had at least one of these risk factors as an indicator or poor prognosis. The distribution of organ involvement was typical for patients with chronic GVHD.
Among the 668 patients, 56% had a treatment change within 2 years after beginning systemic treatment for chronic GVHD, and the median interval time from initial systemic treatment to the first treatment change was 4.4 months (range, 0.3 -54 months) (Figure 2A ). Treatment change was associated with two risk factors: skin involvement at the onset of chronic GVHD and use of 6 a female donor for male recipients ( Table 2 ). The cumulative incidence of non-relapse mortality at 2 years was 16% (95% CI, 13%-19%) ( Figure 2B ), and overall survival at 2 years was 74%
(95% CI, 70%-77%). As shown in Figure 3 , the cumulative incidence of non-relapse mortality was higher for patients who had a treatment change within 4 months after the initiation of systemic treatment for chronic GVHD than for those who did not have a treatment change during the first 4 months (27% versus 12%, respectively).
As expected, time-dependent analysis showed that treatment change after initial systemic treatment for chronic GVHD was associated with an increased risk of non-relapse mortality (Table 3) . Since the median time of treatment change was 4.3 months after initial systemic treatment for chronic GVHD, we evaluated results for patients who had a treatment change before 4 months as compared to change after 4 months. As shown in Table 3 , the association with non-relapse mortality was stronger for early treatment change than for late change, although the difference between early and late change was not statistically significant (p = .06). A similar trend was found when we evaluated results for treatment change before 6 months as compared to treatment change after 6 months (p = .09). When time of change was analyzed continuously, change at 4 months was associated with a 2.5-fold increase in nonrelapse mortality, and for each month of delay in treatment change, this effect on non-relapse mortality was attenuated by a factor of 0.94, equivalent to a 6% reduction per month (Table 3 ).
An association between treatment change and overall mortality was also noted, but the hazard ratios were lower (data not shown). For each month of delay in treatment change, the effect on overall mortality was attenuated by a factor of 0.93.
Discussion
Most phases II studies have relied on "response" as the primary endpoint in clinical trials for chronic GVHD. While "response" is easily recognized in clinical practice, Our results confirmed those reported by Kim et al 11 in demonstrating that exacerbation of chronic GVHD is associated with an increased risk of non-relapse mortality and with decreased overall survival. As in the Korean study, the associations with non-relapse mortality and survival endpoints are stronger for early exacerbation than for late exacerbation. Skin involvement at onset of chronic GVHD and the use of female donor for male recipients were the only risk factors associated with treatment change. Because accrual of the cohort antedated the NIH consensus definition of severity scores for chronic GVHD 12 , these factors could not be analyzed as risk factors for change of therapy and nonrelapse survival in our study.
We evaluated whether early treatment change could be used as a surrogate for nonrelapse mortality in clinical trials (see supplemental Table) . In our cohort, 27% of the patients had a treatment change within 4 months after diagnosis of chronic GVHD, and the risk of nonrelapse mortality at 2 years for these patients was 27%. The contribution to non-relapse mortality at 2 years among these patients is 0.27 x 0.27, or 7%. Among the remaining 73% of patients who did not have a treatment change during the first 4 months, the risk of non-relapse mortality was 12%, and the contribution to non-relapse mortality at 2 years among these patients is 9%. The total non-relapse mortality for both groups at 2 years is 16%. If we had a therapy that could eliminate the need for any treatment change during the first 4 months after diagnosis, the expected non-relapse mortality at 2 years would be 12%, only 4 percentage 8 points lower than historical results. Under the same assumptions, the difference in overall mortality would be only 2 percentage points. When the same analysis was repeated using 1 year (by which time 47% of patients had a treatment change) instead of 4 months as the time point for assessment of treatment change, the difference in NRM at 2 years was only 3
percentage points.
Our results indicate that differences in the strength of associations between early change of treatment and non-relapse mortality or survival are not large enough to allow the use of early exacerbation as a surrogate endpoint for non-relapse mortality or survival in clinical trials for treatment of chronic GVHD. In evaluating our results, it should be noted that the acuity of chronic GVHD was higher in the Korean cohort 11 than in our cohort, as indicated by a higher incidence of progressive onset (38% versus 12%) and thrombocytopenia (49% versus 30%), a higher incidence of exacerbation at 2 years (70% versus 56%), a shorter time to exacerbation, (2.4 versus 4.4 months) and a higher incidence of non-relapse mortality at 2 years (39% versus 16%), respectively. In addition, the previous report included patients with late, persistent or recurrent acute GVHD while our cohort included only patients with classic chronic GVHD and overlap syndrome 12 . These differences might account for the stronger association between early change of treatment and non-relapse mortality in the Korean study than in our study. We conclude that other measures of clinical benefit, such as response, will need to be developed as endpoints in phase II trials of treatment for chronic GVHD. 
